Study Shows Improvement with Benlysta Plus Standard Lupus Treatment
Monday, July 9, 2012
A new study found that belimumab combined with conventional treatment improved biomarkers and clinical disease activity in patients with systemic lupus erythematosus. Study investigators wrote, “Taken together, these results suggest that belimumab treatment does not compromise the immune response to infection." Abstract
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms